Biotechnology and medical device company Blink Science is set to launch a new handheld biosensor device for the immediate detection of Covid-19 and other disease biomarkers in saliva.

Called blinkTEST, the new device is designed to offer health reports that can be analysed immediately to diagnose acute and chronic conditions.

It offers instantaneous results without requiring costly genetic testing.

Most of the point-of-care (POC) testing devices currently available, or that have received emergency use authorisation (EUA), offer tests in well over 20-30 minutes, the company noted.

Blink Science’s device uses a patented electronic technology that will detect a range of biomarkers.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The blinkTEST biosensor can read the electrical charges between antibodies and an easy-to-use test strip.

Blink Science CEO and president Eric Doherty said: “What we are bringing to market is revolutionary. This device will be able to provide the fastest test not only for Covid-19 but also for a number of other viruses and specific disease states.”

Currently, Blink Science is looking to develop strategic licensing and manufacturing relationships to accelerate to the market launch of the new device.

The company also plans to partner with corporate and investment companies for the rapid development of the product.

Blink Science is a SpinUp Campus company, which focuses on connecting university scientists with investors to transform significant research into viable businesses.

SpinUp Campus CEO and founder Billy Meadow said: “I am tremendously excited to have a stellar team led by Eric Doherty to commercialise this amazing molecular diagnostic innovation coming out of the University of Florida. This device will change the global diagnostics industry and save lives.”